- Home
- RLI vs BBIO Comparison
RLI vs BBIO Comparison
Compare RLI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLI
- BBIO
- Stock Information
- Founded
- RLI 1965
- BBIO 2015
- Country
- RLI United States
- BBIO United States
- Employees
- RLI N/A
- BBIO N/A
- Industry
- RLI Property-Casualty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RLI Finance
- BBIO Health Care
- Exchange
- RLI Nasdaq
- BBIO Nasdaq
- Market Cap
- RLI 6.8B
- BBIO 8.0B
- IPO Year
- RLI 1985
- BBIO 2019
- Fundamental
- Price
- RLI $70.41
- BBIO $42.83
- Analyst Decision
- RLI Hold
- BBIO Strong Buy
- Analyst Count
- RLI 8
- BBIO 14
- Target Price
- RLI $78.60
- BBIO $58.85
- AVG Volume (30 Days)
- RLI 500.4K
- BBIO 3.4M
- Earning Date
- RLI 07-21-2025
- BBIO 07-31-2025
- Dividend Yield
- RLI 3.70%
- BBIO N/A
- EPS Growth
- RLI N/A
- BBIO N/A
- EPS
- RLI 3.03
- BBIO N/A
- Revenue
- RLI $1,733,218,000.00
- BBIO $127,415,000.00
- Revenue This Year
- RLI N/A
- BBIO $102.05
- Revenue Next Year
- RLI $5.96
- BBIO $54.69
- P/E Ratio
- RLI $23.18
- BBIO N/A
- Revenue Growth
- RLI 8.88
- BBIO N/A
- 52 Week Low
- RLI $68.50
- BBIO $21.72
- 52 Week High
- RLI $91.15
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- RLI 37.29
- BBIO 62.71
- Support Level
- RLI $70.90
- BBIO $41.80
- Resistance Level
- RLI $72.47
- BBIO $45.48
- Average True Range (ATR)
- RLI 1.27
- BBIO 1.53
- MACD
- RLI -0.16
- BBIO 0.02
- Stochastic Oscillator
- RLI 23.52
- BBIO 61.62
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.